UROONCO PCa associate editor Dr. Constance Thibault (FR) talks to Prof. Christophe Hennequin from Saint-Louis Hospital, France about the GETUG-AFU 18 trial results he presented at ASCO GU24 in San Francisco.
Prof. Hennequin shares details on the design of the study, followed by the trial results of long-term dose escalation (80 vs 70Gy) combined with long-term androgen deprivation in high-risk prostate cancer.
For more details on this study, you can read this abstract on the UROONCO Prostate Cancer educational platform.
UROONCO PCa associate editor Dr. Constance Thibault (FR) talks to Prof. Christophe Hennequin from Saint-Louis Hospital, France about the GETUG-AFU 18 trial results he presented at ASCO GU24 in San Francisco.
Prof. Hennequin shares details on the design of the study, followed by the trial results of long-term dose escalation (80 vs 70Gy) combined with long-term androgen deprivation in high-risk prostate cancer.
For more details on this study, you can read this abstract on the UROONCO Prostate Cancer educational platform.